BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 19, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Janumet: Phase III data

In a double-blind Phase III trial in 517 Type II diabetics, Janumet met the primary endpoint of significantly reducing mean HbA1c from baseline to week 32 vs. Actos pioglitazone (1.9% vs. 1.4%, p<0.001). On secondary endpoints, Janumet led to significantly greater reductions in FPG (56 vs....

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >